---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-088391"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T03:47:59.949552+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology to Advance Onvansertib to First-Line mCRC, Partners with Pfizer Ignite for New Trial

## Summary
- Announces new lead program in first-line RAS-mutated metastatic colorectal cancer with FDA agreement.
- Launches CRDF-004 Phase 2 trial with 90 patients; interim topline results expected mid-2024.
- Pfizer Ignite will support clinical execution; expands relationship from Pfizer's 2021 equity investment.
- Discontinues ONSEMBLE second-line trial to focus resources on first-line program.
- Cash position of $89.4M as of June 30, 2023, sufficient to fund operations into 2025.

## SEC filing metadata
- accession: 0001104659-23-088391
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000110465923088391/0001104659-23-088391-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000110465923088391/tm2322922d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-088391
- JSON: https://secwatch.observer/filing/0001104659-23-088391.json
- Plain text: https://secwatch.observer/filing/0001104659-23-088391.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.